chufangao/CTO huggingface dataset:
Clinical trial NCT04269707: Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
Official title: Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron Under Study Protocol 1VIT17044
Sponsor: American Regent, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-19
Primary completion date: 2020-12-30
Completion date: 2021-01-29
Clinical trial NCT04249713: An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
Official title: An Alternative Dose Interval Study to Examine Safety and Identify Potential Biomarkers in Participants With Hidradenitis Suppurativa Receiving Brodalumab
Sponsor: Rockefeller University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Biomarker Samples Not Collected
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-03
Primary completion date: 2020-07-31
Completion date: 2020-09-30
Plan to share individual participant data: NO
Clinical trial NCT01649388: A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
Official title: A Single-arm, Multi-center, Exploratory Safety and Efficacy Study of FCR001 Cell-based Therapy to Induce Donor-specific Tolerance in Previously Transplanted Recipients of a Kidney From a Living Donor, and Safety in FCR001 Donors
Acronym: FREEDOM-2
Sponsor: Talaris Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: study terminated by sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-10-15
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT04205435: β-globin Restored Autologous HSC in β-thalassemia Major Patients
Official title: a Safety and Efficacy Study of β-globin Restored Autologous Hematopoietic Stem Cells for β-thalassemia Major Patients With CVS-654 Mutation
Sponsor: Bioray Laboratories (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-01
Primary completion date: 2022-06-01
Completion date: 2022-07-25
Plan to share individual participant data: NO
Clinical trial NCT04242173: Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Official title: A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Interest
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-25
Primary completion date: 2022-05-26
Completion date: 2022-05-26
Baseline population: Study terminated early due to lack of interest
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04594811: NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
Official title: A Multicenter, Open-label, Phase 1 Dose Escalation ,Phase 2 Study of NT-I7 in Combination With Nivolumab in Subjects With Relapsed/Refractory Gastric or Gastro-Esophageal Junction or Esophageal Adenocarcinoma Who Progressed on or Intolerant to 2 or More Prior Lines of Systemic Therapy
Sponsor: NeoImmuneTech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company strategic decision
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-21
Primary completion date: 2023-05-26
Completion date: 2023-05-26
Clinical trial NCT04558684: Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Official title: Short Course Radiotherapy With Total Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Sponsor: Wuhan Union Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Inadequate patient enrollment
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-01
Primary completion date: 2020-09-30
Completion date: 2023-12-30
Clinical trial NCT02611960: Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Official title: A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 233.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-18
Primary completion date: 2020-11-30
Completion date: 2022-09-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04377945: Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
Official title: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components
Acronym: SHINE
Sponsor: Bukwang Pharmaceutical (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 41.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-04-28
Primary completion date: 2024-02-14
Completion date: 2024-02-14
Plan to share individual participant data: NO
Clinical trial NCT03145064: Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Official title: A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2019-05-24
Completion date: 2020-09-03
Plan to share individual participant data: YES
Clinical trial NCT03057509: A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Official title: A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Slow accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-30
Primary completion date: 2019-10-31
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT04052139: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin
Official title: Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems
Acronym: UH3
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-25
Primary completion date: 2021-11-16
Completion date: 2021-12-15
Plan to share individual participant data: YES
IPD sharing description: All data from the study will be placed into the URBAN ARCH repository.
Clinical trial NCT02966314: Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
Official title: A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-30
Primary completion date: 2020-01-06
Completion date: 2020-01-06
Baseline population: Two participants enrolled onto the study were screened but not randomized to an arm.
Plan to share individual participant data: NO
Clinical trial NCT05005910: Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis
Official title: Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis
Sponsor: Mahidol University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 194.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2022-12-01
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT03949842: Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study
Official title: A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Acronym: LEGEND
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-27
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT05296733: A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
Official title: A Non-randomised, Open-label, 2-part, Parallel-cohort Trial to Evaluate 1) Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of BI 456906 in Patients With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Healthy Subjects With and Without Overweight/Obesity and 2) Safety and Tolerability of Multiple Subcutaneous Doses of BI 456906 in Patients With Overweight/Obesity With Cirrhosis and Varying Degrees of Hepatic Impairment Relative to Patients With Overweight/Obesity Without Cirrhosis/Hepatic Impairment
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 7.0
Start date: 2022-04-27
Primary completion date: 2023-12-29
Completion date: 2023-12-29
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).~For more details refer to:~https://www.mystudywindow.com/msw/datatransparency
Clinical trial NCT04449861: Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
Official title: An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 166.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-07
Primary completion date: 2023-03-30
Completion date: 2023-03-30
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04398316: High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department
Official title: High Dose Intravenous Lidocaine vs Hydromorphone for Acute Abdominal Pain in the Emergency Department: A Randomized, Comparative Efficacy Trial
Acronym: HIDO-LIDO
Sponsor: Hennepin Healthcare Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Administrative
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-18
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Limitations and caveats: No statistical analysis was done due to enrolling only 4 subjects before the trial was terminated.
Plan to share individual participant data: NO
Clinical trial NCT03242889: A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Official title: A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-10
Primary completion date: 2017-11-01
Completion date: 2023-02-10
Clinical trial NCT03792503: Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
Official title: Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study
Sponsor: Xinqiao Hospital of Chongqing (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: abandon
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-28
Primary completion date: 2020-02-29
Completion date: 2022-02-28
Clinical trial NCT04171765: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
Official title: A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis
Acronym: BANFF
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to strategic business reasons.
Enrollment: 46.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-30
Primary completion date: 2023-01-23
Completion date: 2023-01-23
Limitations and caveats: Because the study was terminated early, the interpretation of its data is limited, and early dropout may confound the results.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02398656: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Official title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Acronym: TEMPO-2
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 886.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-01
Primary completion date: 2024-01-19
Completion date: 2024-04-10
Plan to share individual participant data: NO
IPD sharing description: Overall data will be shared once the trial has been closed and data analysed. No individual participant data will be available.
Clinical trial NCT03063203: Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Official title: An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-14
Primary completion date: 2021-02-13
Completion date: 2022-03-16
Plan to share individual participant data: NO
Clinical trial NCT03139370: Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Official title: A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to the sponsor's decision to discontinue the clinical trial.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-27
Primary completion date: 2021-06-30
Completion date: 2023-06-04
Plan to share individual participant data: NO
Clinical trial NCT02714530: Thoracal Radiotherapy and Tarceva
Official title: Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer
Acronym: ThoRaT
Sponsor: Oslo University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 118.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-04-01
Primary completion date: 2020-12-30
Completion date: 2020-12-30
Plan to share individual participant data: YES
IPD sharing description: Publish results
Clinical trial NCT03633617: Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Official title: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 321.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-24
Primary completion date: 2021-09-09
Completion date: 2022-06-07
Baseline population: Part A Full analysis set (FAS) includes all randomized participants in Part A; Part B FAS includes all randomized participants in Part B. Participants who participated in Part A were not eligible to participate in Part B.
Clinical trial NCT04718961: A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Official title: A Phase 2a/2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA).
Acronym: OHANA
Sponsor: Mirum Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to company's assessment of enrollment feasibility.
Enrollment: 4.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-01-04
Primary completion date: 2022-12-07
Completion date: 2022-12-07
Baseline population: Part 2 was early terminated due to lack of enrollment and the company's assessment of enrollment feasibility.
Clinical trial NCT04562467: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
Official title: The Icosapent Ethyl and Prevention of Vascular Regenerative Cell Exhaustion Study
Acronym: IPE-PREVENTION
Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-24
Primary completion date: 2023-05-25
Completion date: 2023-05-25
Plan to share individual participant data: NO
Clinical trial NCT04001517: Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Official title: A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Acronym: AscenD-LB
Sponsor: EIP Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04831450: Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
Official title: Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Investigator Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-31
Primary completion date: 2022-07-15
Completion date: 2022-07-15
Plan to share individual participant data: NO
Clinical trial NCT05292755: Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome
Official title: Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome: a Randomized, Controlled, Double-Blind Study
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-22
Primary completion date: 2022-05-30
Completion date: 2022-07-01
Plan to share individual participant data: NO
Clinical trial NCT03036904: Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Official title: Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Acronym: V+DA-EPOCH-R
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-06
Primary completion date: 2021-11-11
Completion date: 2021-11-11
Plan to share individual participant data: NO